Pre-Diabetes Risk Score effectively combats type 2 diabetes in Qatar

(MENAFN) A recent study has unveiled the potential of a new tool, the Pre-Diabetes Risk Score in Qatar (PRISQ), in effectively combating the prevalence of type 2 diabetes in Qatar and potentially beyond. Developed using clinical data from Qatar Biobank and relying solely on non-invasive parameters, PRISQ has demonstrated an impressive ability to diagnose pre-diabetes in over 90 percent of individuals in real clinical settings.

Published in the BMJ Public Health journal, the study titled "Real-world clinical validation of the Qatar pre-diabetes risk score: a cross-sectional study" underscores PRISQ's role as a robust solution for rapid and cost-effective pre-diabetes diagnosis. By utilizing non-invasive parameters exclusively, PRISQ offers a practical approach to identifying individuals at risk of developing type 2 diabetes early on.

Pre-diabetes, characterized by elevated blood sugar levels that do not yet meet the threshold for type 2 diabetes, poses a significant health risk. Individuals with pre-diabetes are more susceptible to progressing to full-blown diabetes compared to those with normal blood sugar levels. Therefore, effective management of pre-diabetes through lifestyle modifications such as diet and exercise can substantially mitigate the risk of developing type 2 diabetes, emphasizing the critical need for early intervention strategies.

The introduction of PRISQ represents a promising advancement in diabetes prevention efforts, particularly in regions like Qatar where diabetes prevalence is a major public health concern. By enabling early identification and proactive management of pre-diabetes, PRISQ has the potential to significantly reduce the burden of type 2 diabetes and improve long-term health outcomes for individuals at risk.

MENAFN03072024000045015839ID1108402428